-
Chiral Chemistry: in the DNA of Symeres
Over 50% of current drugs in development are chiral. At Symeres we apply a suite of state-of-the-art technologies to obtain the desired chiral compound in high enantiomeric purity. For decades, Symeres has been supporting the global pharma and biotech industry with the synthesis and delivery of chiral compounds, both through synthesis and purification strategies.
-
Interview with Richard Blaauw, Director of Operations at Organix
In April 2022, Symeres acquired Organix, a US-based CRO specializing in lipid synthesis. To aid in the incorporation of Organix into the Symeres family, and facilitate future growth transitions, Richard Blaauw has been appointed to the newly created position of Director of Operations.
-
Symeres Weert receives new GMP certificate
This week, our facility in Weert NL received a new certificate of GMP compliance from the Dutch authorities.
-
A decade of integrated drug discovery at Symeres
Symeres celebrates a decade of integrated drug discovery. Our team has been working hard to provide our clients with the best possible solutions for their needs.
-
Symeres welcomes Karen Damian to the team
We introduce you to our newest Director of Business Development. Karen Damian has a history in the drug development life sciences business.
-
π-Facial selectivity in the Diels–Alder reaction of glucosamine-based chiral furans and maleimides
Symeres explorations into opportunities to access novel chemical space by using carbohydrates as sustainable chiral starting materials for library synthesis has led to yet another publication.
-
An interview with Yadan Chen and Paul O’Shea
We are pleased to introduce the founders of Symeres’ daughter company Exemplify in New Jersey: Yadan Chen, CEO, and Paul O’Shea, Chief Scientific Officer. Who are they? What do they stand for? And how does Exemplify fit with Symeres?
-
We’re expanding our laboratory facilities in Boston
To continue supporting our clients, our daughter company Organix needs more room. The new facility will help us expand our services.
-
Symeres acquires Oncolines, further strengthening its drug discovery and biology capabilities
We are proud to announce the acquisition of Oncolines, a Netherlands-based CRO that provides early biology services and cell-line profiling assays.
-
Symeres CZ passed commercial inspection
We’re very keen on keeping our GMP facilities up to date according to the latest standards.
-
Symeres acquires Exemplify BioPharma, further strengthening its strategic foothold in the US
Another strategic move. Exemplify has expertise and consultancy services in Process Chemistry, expertise and consultancy services in Process Chemistry, Analytical Chemistry, and Formulation Development.
-
Symeres to host final of Dutch Chemistry Olympiad 2025
What seems far away will be here before you know it. With our footprint in the Netherlands and our roots in chemistry, we are proud to have been asked to sponsor this event.
Feel free to contact us!
Curious to know more about what can we do for you? Get in touch and let’s start a conversation.
